Patents by Inventor John J. Baldwin

John J. Baldwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5177092
    Abstract: Azole compounds including azoles and azolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: June 17, 1991
    Date of Patent: January 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: David C. Remy, John J. Baldwin, David A. Claremon, Stella W. King
  • Patent number: 5175284
    Abstract: Intermediates are described for preparing conformationally constrained tricyclic thienothiopyran compounds that are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and glaucoma associated therewith.
    Type: Grant
    Filed: October 15, 1991
    Date of Patent: December 29, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, Kenneth L. Shepard, Theresa M. Williams
  • Patent number: 5152988
    Abstract: The use of imidazoles of the formula ##STR1## and imidazolium salts of the formula ##STR2## in thromobolytic therapy are described.
    Type: Grant
    Filed: February 20, 1991
    Date of Patent: October 6, 1992
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, David C. Remy, John J. Baldwin
  • Patent number: 5120757
    Abstract: Carbonic anhydrase inhibitors of the thieno[2,3-b]thiopyran-2-sulfonamide type with a substituted-alkyl-amino group in the 4-position are topically effective in lowering intraocular pressure.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: June 9, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello
  • Patent number: 5114919
    Abstract: Various cyproheptadine derivatives sensitize multidrug resistant cells to certain chemotherapeutic agents. As such, these cyproheptadine derivatives are useful as adjuncts in the reversal of multidrug resistance in mammalian tumor cells either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with anticancer chemotherapeutic agents or compounds.
    Type: Grant
    Filed: February 11, 1991
    Date of Patent: May 19, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy
  • Patent number: 5112824
    Abstract: Compounds of structural formula: ##STR1## wherein R' is hydrogen or an aromatic ring system, and Q is a substituted nitrogen or a nitrogen containing heterocycle, X and Y are bridging groups and p is 0 or 1, and E is --S-- or --O--, are Class III antiarrhythmic agents.
    Type: Grant
    Filed: July 15, 1991
    Date of Patent: May 12, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Harold G. Selnick, Gerald S. Ponticello, David C. Remy, David A. Claremon, Jason M. Elliott
  • Patent number: 5098707
    Abstract: Compositions useful for thrombolytic therapy comprising a plasminogen activator such as tPA or streptokinase together with an imidazolium salt having the formula ##STR1## in a pharmaceutically acceptable carrier and methods for inhibiting hard clot formation or supplementing fibrinolytic therapy are described. The imidazolium salt also may be used with a platelet aggregation inhibitor or anticoagulant.
    Type: Grant
    Filed: April 29, 1991
    Date of Patent: March 24, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy, David A. Claremon
  • Patent number: 5091409
    Abstract: 4-Alkylamino-6-(C.sub.3-5 -hydrocarbyl)thieno[2,3-b]thiopyran-2-sulfonamide-7,7-dioxides wherein the 4-alkylamino group is an ethylamino or propylamino are powerful carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and glaucoma associated therewith.
    Type: Grant
    Filed: May 17, 1990
    Date of Patent: February 25, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, Kenneth L. Shepard, Theresa M. Williams
  • Patent number: 5084444
    Abstract: Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: June 10, 1991
    Date of Patent: January 28, 1992
    Assignee: Merck & Co. Inc.
    Inventors: David A. Claremon, John J. Baldwin, David C. Remy
  • Patent number: 5077285
    Abstract: Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: December 31, 1991
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, David C. Remy, John J. Baldwin
  • Patent number: 5047416
    Abstract: Azole compounds including azoles and azolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: September 10, 1991
    Assignee: Merck & Co., Inc.
    Inventors: David C. Remy, John J. Baldwin, David A. Claremon, Stella W. King
  • Patent number: 5045561
    Abstract: Furan sulfonamides with a saturated heterocycle fused thereto are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure.
    Type: Grant
    Filed: April 12, 1990
    Date of Patent: September 3, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, Harold G. Selnick
  • Patent number: 5032598
    Abstract: Compounds of structural formula: ##STR1## wherein Ar is an aromatic ring, B is a cyclic moiety fused to Ar of 5-7 members and Q is a nitrogen containing heterocycle, are antiarrhythmic agents.
    Type: Grant
    Filed: December 8, 1989
    Date of Patent: July 16, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Gerald S. Ponticello, David C. Remy, Harold G. Selnick
  • Patent number: 5032604
    Abstract: Compounds of structural formula: ##STR1## wherein R' is hydrogen or an aromatic ring system, and Q is a substituted nitrogen or a nitrogen containing heterocycle, and E is --S-- or --O--, are Class III antiarrhythmic agents.
    Type: Grant
    Filed: December 8, 1989
    Date of Patent: July 16, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Gerald S. Ponticello, David C. Remy, Harold G. Selnick
  • Patent number: 5030644
    Abstract: Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: July 9, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy, David A. Claremon
  • Patent number: 5021440
    Abstract: Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: June 4, 1991
    Assignee: Merck & Co., Inc.
    Inventors: David C. Remy, John J. Baldwin, David A. Claremon, Stella W. King
  • Patent number: 5021426
    Abstract: Various 3-substituted cyproheptadine derivatives are useful in the treatment of infection by Plasmodium falciparum and in the treatment of malaria either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with antimalarial agents or compounds. Methods of treating malaria and methods of treating infection by Plasmodium falciparum are also described.
    Type: Grant
    Filed: February 26, 1990
    Date of Patent: June 4, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gabriel F. Eilon, Paul A. Friedman, David C. Remy
  • Patent number: 5019572
    Abstract: Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: February 7, 1990
    Date of Patent: May 28, 1991
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, John J. Baldwin, David C. Remy
  • Patent number: 4996321
    Abstract: Various cyproheptadine derivatives sensitize multidrug resistant cells to certain chemotherapeutic agents. As such, these cyproheptadine derivatives are useful as adjuncts in the reversal of multidrug resistance in mammalian tumor cells either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with anticancer chemotherapeutic agents or compounds.
    Type: Grant
    Filed: February 26, 1990
    Date of Patent: February 26, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy
  • Patent number: 4994464
    Abstract: Certain piperazinylpyrimidines have pronounced .beta.-adrenergic blocking properties and some of the compounds are particularly useful in the treatment of elevated intraocular pressure and glaucoma.
    Type: Grant
    Filed: October 5, 1989
    Date of Patent: February 19, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Tolman, John J. Baldwin, Arthur F. Wagner, Adolph Pietruszkiewicz